WOLVERINE TRADING, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 310 filers reported holding CRISPR THERAPEUTICS AG in Q3 2020. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.

Quarter-by-quarter ownership
WOLVERINE TRADING, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$5,776,331
-13.8%
127,260
+8.3%
0.01%
-25.0%
Q2 2023$6,699,907
+191819.4%
117,501
+48.7%
0.01%
+33.3%
Q1 2023$3,491
-8.2%
79,041
-15.5%
0.01%
+20.0%
Q4 2022$3,802
-99.9%
93,526
-5.0%
0.01%
-50.0%
Q3 2022$6,351,000
-16.3%
98,472
-18.3%
0.01%
-23.1%
Q2 2022$7,592,000
-16.1%
120,512
-14.7%
0.01%
+8.3%
Q1 2022$9,050,000
-42.9%
141,236
-29.8%
0.01%
-36.8%
Q4 2021$15,855,000
-23.5%
201,086
+6.9%
0.02%
-17.4%
Q3 2021$20,721,000
-40.8%
188,028
-19.2%
0.02%
-57.4%
Q2 2021$35,020,000
+26.3%
232,702
-3.3%
0.05%
+25.6%
Q1 2021$27,735,000
+9.5%
240,751
+53.6%
0.04%
+7.5%
Q4 2020$25,325,000
+302.5%
156,747
+111.7%
0.04%
+166.7%
Q3 2020$6,292,000
-4.1%
74,035
-15.3%
0.02%
-16.7%
Q2 2020$6,564,000
+122.0%
87,456
+31.0%
0.02%
+100.0%
Q1 2020$2,957,000
-15.2%
66,773
+18.5%
0.01%
+12.5%
Q4 2019$3,485,000
+36.6%
56,357
-6.4%
0.01%0.0%
Q3 2019$2,551,000
-33.7%
60,200
-26.3%
0.01%
-27.3%
Q2 2019$3,848,000
+67.5%
81,700
+27.1%
0.01%
+83.3%
Q1 2019$2,297,000
+44.1%
64,300
+7.9%
0.01%
+50.0%
Q4 2018$1,594,000
-40.0%
59,600
-0.5%
0.00%
-33.3%
Q3 2018$2,655,00059,8710.01%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2020
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders